A Retrospective Analysis of Renal Function, Tac Dose Adjustments and CYP3A5 Pharmacogenetics in Stable Renal Transplant Recipients Converted From Tac BID to Tac OD
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Tacrolimus (Primary)
- Indications Transplant rejection
- Focus Pharmacodynamics; Pharmacogenomic
- 18 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 13 Aug 2013 New trial record